Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Wakefulness-promoting agents for residual sleepiness
5 evidence topics · 4 sources
VA/DoD 2025 recommendation for armodafinil, modafinil, or solriamfetol
Confirming adherence and efficacy of airway treatment before adding a wake-promoting agent
Solriamfetol label: indication and limitation of use in OSA
Armodafinil label: indication and limitation of use in OSA
Wake-promoting agents outside the scope of the ERS 2021 guideline
“In addition, several drugs address the problem of residual sleepiness despite optimal treatment of the underlying disease [103–105]. Unfortunately, these findings could not be included in this project as they do not focus on the causal treatment of the disease itself and major studies were published after the time limit of the literature searches.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote